Importance Multiple sclerosis (MS) is an autoimmune-mediated neurodegenerative disease
of the central nervous system characterized by inflammatory demyelination with axonal …

Personalized treatment is ideal for multiple sclerosis (MS) owing to the heterogeneity of
clinical features, but current knowledge gaps, including validation of biomarkers and …

Importance Accumulation of disability in multiple sclerosis may occur as relapse-associated
worsening (RAW) or steady progression independent of relapse activity (PIRA), with PIRA …

Background B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a
humanized monoclonal antibody that selectively depletes CD20+ B cells. Methods In two …

Objective Rates of worsening and evolution to secondary progressive multiple sclerosis
(MS) may be substantially lower in actively treated patients compared to natural history …

Objective Gray matter (GM) atrophy occurs in all multiple sclerosis (MS) phenotypes. We
investigated whether there is a spatiotemporal pattern of GM atrophy that is associated with …

Importance There is a lack of validated biomarkers for disability progression independent of
relapse activity (PIRA) in multiple sclerosis (MS). Objective To determine how serum glial …

Importance Uncertainty remains about how aggressively to treat early multiple sclerosis.
High-efficacy disease-modifying therapies (DMTs) are often reserved for individuals …

Background Serum neurofilament light chain (sNfL) is a biomarker of neuronal damage that
is used not only to monitor disease activity and response to drugs and to prognosticate …

Monoclonal antibodies that target CD20 expressing B cells represent an important new
treatment option for patients with multiple sclerosis (MS). B‐cell‐depleting therapy is highly …